Currently, the biomarkers used to predict the efficacy of PD-1/PD-L1 monoclonal antibodies include immunohistochemical expression levels of PD-L1 (CPS) (Kim et al., 2018), high microsatellite instability (MSI-H) (Diaz Jr and Le, 2015), and tumor mutational load (TMB) (Samstein et al., 2019). This evidence concerns the gene CD274 and neoplasm.